scholarly journals Oral Rehydration Therapy Utilization and Associated Factors Among Children with Diarrhea in Debre Berhan, Ethiopia, 2020

2021 ◽  
Vol Volume 12 ◽  
pp. 251-258
Author(s):  
Abate Dargie Wubetu ◽  
Abayneh Shewangzaw Engda ◽  
Hailu Belay Yigzaw ◽  
Getaneh Baye Mulu

2001 ◽  
Vol 77 (6) ◽  
pp. 481-6
Author(s):  
Lauro Virgílio de Sena ◽  
Helcio de S. Maranhão ◽  
Mauro B. Morais


2021 ◽  
Vol 6 (1) ◽  
pp. 34
Author(s):  
David Nalin

The original studies demonstrating the efficacy of oral glucose-electrolytes solutions in reducing or eliminating the need for intravenous therapy to correct dehydration caused by acute watery diarrheas (AWD) were focused chiefly on cholera patients. Later research adapted the oral therapy (ORT) methodology for treatment of non-cholera AWDs including for pediatric patients. These adaptations included the 2:1 regimen using 2 parts of the original WHO oral rehydration solution (ORS) formulation followed by 1 part additional plain water, and a “low sodium” packet formulation with similar average electrolyte and glucose concentrations when dissolved in the recommended volume of water. The programmatic desire for a single ORS packet formulation has led to controversy over use of the “low sodium” formulations to treat cholera patients. This is the subject of the current review, with the conclusion that use of the low-sodium ORS to treat cholera patients leads to negative sodium balance, leading to hyponatremia and, in severe cases, particularly in pediatric cholera, to seizures and other complications of sodium depletion. Therefore it is recommended that two separate ORS packet formulations be used, one for cholera therapy and the other for non-cholera pediatric AWD.



2002 ◽  
Vol 156 (12) ◽  
pp. 1177 ◽  
Author(s):  
Mathuram Santosham


1983 ◽  
Vol 74 (5) ◽  
pp. 335-341 ◽  
Author(s):  
Jay Swedberg ◽  
Joseph F. Steiner


2017 ◽  
Vol 36 (3) ◽  
pp. 250-255 ◽  
Author(s):  
Dillip Kumar Dash ◽  
Mrutunjaya Dash ◽  
M.D. Mohanty ◽  
Naresh Acharya

Introduction: Administration of S. boulardii in addition to rehydration therapy in diarrhea found to be beneficial in many aspects owing to a variety of causes and importantly it is was not associated with any adverse effects.Material and Methods: We conducted a prospective study of children suffering from acute diarrhoea, at a private tertiary care hospital. Children were divided into 2 groups randomly as per odd(Group 1 ) and even (Group 2) bed allotted in indoor at the time of admission: Group 1 included children on oral rehydration therapy (ORT) + Zinc + Saccharomyces boulardii (Probiotic 5 billion CFU twice daily) and Group 2 comprised of children on ORT+ Zinc. Our objective was to systematically review data on the effect of S. boulardii on acute childhood diarrhoea.Results: Out of a total of 126 children less than 2 years, 2-6 years and 6-14 years were 72 (57.14%), 42(33.33%) and 12(09.52%) respectively. The duration of diarrhoea in Group 1 was 26.31 hours and Group 2 was 47.81 hours (p<0.01). The frequency of diarrhoea showed improvement within 24 and 72 hours in Group 1 and Group 2 respectively (p<0.01).Similarly, the mean duration of hospital stay was 2.68 days in Group 1 and 4.8 days in Group 2.The treatment cost was INR 850 and INR 1650 while social cost was INR 1250 and 2600 in Group 1 and 2 respectively.Conclusion:This study shows that S. boulardii reduced the duration, frequency and hospital stay of diarrhoea thereby reducing the treatment and social costs.J Nepal Paediatr Soc 2016;36(3):250-255



The Lancet ◽  
1992 ◽  
Vol 339 (8798) ◽  
pp. 936
Author(s):  
M.J.G. Farthing


1994 ◽  
Vol 112 (3) ◽  
pp. 463-471 ◽  
Author(s):  
D. Mahalanabis ◽  
A. S. G. Faruque ◽  
M. J. Albert ◽  
M. A. Salam ◽  
S. S. Hoque

SUMMARYWe describe the disease spectrum and socio-demographic and epidemiological features of an epidemic of cholera due to a new pathogen.Vibrio choleraeO139, in patients attending a very large hospital in the metropolitan city of Dhaka, Bangladesh.This hospital treats 70000–90000 patients a year with diarrhoeal diseases. A 4% systematic sample of 1854 patients attending from January to April 1993 were studied.Five hundred and two (27%) of the 1854 patients were culture positive forV. choleraeO139 and 63 (3%) were culture positive forV. choleraeO1 biotype El Tor. Patients withV. choleraeO139 were mainly adults with a short history of watery diarrhoea. Eight-three percent of patients had moderate to severe dehydration. All recovered except one 80-year-old man with compromised renal function who died. Seventy-eight percent of patients required initial intravenous rehydration followed by oral rehydration therapy with rice ORS; they also received tetracycline to reduce diarrhoea severity. Most patients were from urban slums with inadequate sanitation facilities and hygiene practices.The newly recognizedV. choleraeO139 infection produced an epidemic of severe dehydrating diarrhoea indistinguishable from clinical cholera in a population which experiences two epidemic peaks of cholera in a year due toV. choleraeO1. Infection with the latter does not appear to confer any cross-protection fromV. choleraeO139. The new pathogen suppressed, albeit temporarily,V. choleraeO1. Unlike other non-O1 serogroups ofV. choleraethis new serogroup appears to have epidemic potential.



Sign in / Sign up

Export Citation Format

Share Document